FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
FDA Grants Merus Breakthrough Therapy Designation For Petosemtamab For Treatment Of Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.